

| Trial | Drug (if applicable) | Patent No. | Filed Date | Petitioner(s) | Patent Owner(s) | Inst. Dec. | Outcome | Details of FWD |
|--|---------------------------------------|------------|------------|--|----------------------------|------------|--------------------------|----------------|
| <Information obtained primarily from Lex Machina™ and public sources on the Internet. If any errors are identified, please contact Lisa Mandrusiak at Oblon.> | | | | | | | | |
| IPR2018-00002 | Humira® | 9,512,216 | 2-Oct-17 | Sandoz, Inc. | AbbVie Biotechnology Ltd. | Denied | N/A | N/A |
| IPR2018-00016 | Herceptin® | 7,846,441 | 3-Oct-17 | Pfizer, Inc. | Genentech, Inc. | Denied | N/A | N/A |
| IPR2018-00019 | | 6,221,581 | 4-Oct-17 | Hologic, Inc.; Gen-Probe Incorporated | Enzo Life Sciences Inc. | Denied | N/A | N/A |
| IPR2018-00079 | Myrbetriq® | 6,346,532 | 16-Oct-17 | Sawai USA, Inc.; Sawai Pharmaceutical Co., Ltd. | Astellas Pharma US, Inc. | Denied | N/A | N/A |
| IPR2018-00080 | Uceris® | 9,320,716 | 20-Oct-17 | APS GP LLC; Argentum Pharmaceuticals LLC; APS GP Investors LLC; et al. | Cosmo Technologies Ltd. | N/A | Settled pre-institution | N/A |
| IPR2018-00086 | Rituxan™ | 8,545,843 | 2-Nov-17 | Pfizer, Inc. | Biogen, Inc. | Denied | Pending | N/A |
| IPR2018-00103 | Sovaldi®; Harvoni®; Epclusa®; Vosevi™ | 7,429,572 | 25-Oct-17 | Laura and John Arnold Foundation; Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | Gilead Pharmasset LLC | Denied | N/A | N/A |
| IPR2018-00112 | | 9,623,414 | 23-Oct-17 | Thermo Fisher Scientific, Inc. | Bio-Rad Laboratories, Inc. | N/A | Settled pre-institution | N/A |
| IPR2018-00113 | | 9,623,414 | 23-Oct-17 | Thermo Fisher Scientific, Inc. | Bio-Rad Laboratories, Inc. | N/A | Pending | N/A |
| IPR2018-00115 | | 9,592,308 | 17-Nov-17 | Eli Lilly & Co.; Avid Radiopharmaceuticals, Inc. | Piramal Imaging SA | Instituted | Settled post-institution | N/A |
| IPR2018-00119 | Sovaldi®; Harvoni®; Epclusa®; Vosevi™ | 7,964,580 | 25-Oct-17 | Laura and John Arnold Foundation; Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | Gilead Pharmasset LLC | Denied | N/A | N/A |
| IPR2018-00120 | Sovaldi®; Harvoni®; Epclusa®; Vosevi™ | 7,964,580 | 25-Oct-17 | Laura and John Arnold Foundation; Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | Gilead Pharmasset LLC | Denied | N/A | N/A |
| IPR2018-00121 | Sovaldi®; Harvoni®; Epclusa®; Vosevi™ | 8,334,270 | 26-Oct-17 | Laura and John Arnold Foundation; Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | Gilead Pharmasset LLC | Denied | N/A | N/A |
| IPR2018-00122 | Sovaldi®; Harvoni®; Epclusa®; Vosevi™ | 8,334,270 | 26-Oct-17 | Laura and John Arnold Foundation; Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | Gilead Pharmasset LLC | Denied | N/A | N/A |
| IPR2018-00123 | Harvoni®; Epclusa®; Vosevi™ | 8,735,372 | 9-Nov-17 | Laura and John Arnold Foundation; Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | Gilead Pharmasset LLC | Denied | N/A | N/A |

| | | | | | | | | | |
|---------------|--|-----------|-----------|---|------------------------------|-----------------------------|------------------------|-------------------------|-----|
| IPR2018-00125 | Sovaldi®; Harvoni®; Epclusa®; Vosevi™ | 8,633,309 | 30-Oct-17 | Laura and John Arnold Foundation; Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | Gilead Pharmasset LLC | Denied | N/A | N/A | |
| IPR2018-00126 | Sovaldi®; Harvoni®; Epclusa®; Vosevi™ | 9,284,342 | 2-Nov-17 | Laura and John Arnold Foundation; Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | Gilead Pharmasset LLC | Denied | N/A | N/A | |
| IPR2018-00151 | Abraxane® | 8,138,229 | 9-Nov-17 | Apotex Pharmaceuticals Holdings Inc.; Panacea Biotec Ltd.; Apotex Inc.; et al. | Abraxis Bioscience LC | Denied | N/A | N/A | |
| IPR2018-00152 | Abraxane® | 7,820,788 | 9-Nov-17 | Apotex Pharmaceuticals Holdings Inc.; Panacea Biotec Ltd.; Apotex Inc.; et al. | Abraxis Bioscience LC | Denied | N/A | N/A | |
| IPR2018-00153 | Abraxane® | 7,923,536 | 9-Nov-17 | Apotex Pharmaceuticals Holdings Inc.; Panacea Biotec Ltd.; Apotex Inc.; et al. | Abraxis Bioscience LC | Denied | N/A | N/A | |
| IPR2018-00156 | Humira® | 9,187,559 | 6-Nov-17 | Sandoz, Inc. | AbbVie Biotechnology Ltd. | Denied | N/A | N/A | |
| IPR2018-00162 | Abraxane® | 7,820,788 | 9-Nov-17 | InvaGen Pharmaceuticals, Inc.; Cipla Ltd.; Cipla (EU) Limited; Cipla USA, Inc. | Abraxis Bioscience LC | Denied | N/A | N/A | |
| IPR2018-00163 | Abraxane® | 7,923,536 | 9-Nov-17 | InvaGen Pharmaceuticals, Inc.; Cipla Ltd.; Cipla (EU) Limited; Cipla USA, Inc. | Abraxis Bioscience LC | Denied | N/A | N/A | |
| IPR2018-00164 | Abraxane® | 8,138,229 | 9-Nov-17 | InvaGen Pharmaceuticals, Inc.; Cipla Ltd.; Cipla (EU) Limited; Cipla USA, Inc. | Abraxis Bioscience LC | Denied | N/A | N/A | |
| IPR2018-00168 | Kerydin™ | 9,549,938 | 21-Nov-17 | Wicker Pharmaceuticals LLC; Rajneesh Ahuja; FlatWing Pharmaceuticals, LLC | Anacor Pharmaceuticals, Inc. | Instituted | Final written decision | All claims unpatentable | |
| IPR2018-00169 | Kerydin™ | 9,566,289 | 21-Nov-17 | Wicker Pharmaceuticals LLC; Rajneesh Ahuja; FlatWing Pharmaceuticals, LLC | Anacor Pharmaceuticals, Inc. | Instituted | Final written decision | All claims unpatentable | |
| IPR2018-00170 | Kerydin™ | 9,566,290 | 21-Nov-17 | Wicker Pharmaceuticals LLC; Rajneesh Ahuja; FlatWing Pharmaceuticals, LLC | Anacor Pharmaceuticals, Inc. | Instituted | Final written decision | All claims unpatentable | |
| IPR2018-00171 | Kerydin™ | 9,572,823 | 21-Nov-17 | Wicker Pharmaceuticals LLC; Rajneesh Ahuja; FlatWing Pharmaceuticals, LLC | Anacor Pharmaceuticals, Inc. | Instituted | Final written decision | All claims unpatentable | |
| IPR2018-00173 | Minivelle™ | 9,724,310 | 4-Dec-17 | Mylan N.V.; Mylan, Inc.; Mylan Pharmaceuticals, Inc.; | Mylan Technologies, Inc. | Noven Pharmaceuticals, Inc. | Denied | N/A | N/A |

| | | | | | | | | |
|---------------|------------|-----------|-----------|--|---|------------|--------------------------|-------------------------|
| IPR2018-00174 | Minivelle™ | 9,730,900 | 4-Dec-17 | Mylan N.V.; Mylan, Inc.; Mylan Pharmaceuticals, Inc.; Mylan Technologies, Inc. | Noven Pharmaceuticals, Inc. | Denied | N/A | N/A |
| IPR2018-00182 | | 9,382,220 | 18-Dec-17 | Provepharm Life Solutions; Provepharm SAS; Provepharm Inc. | Wista Laboratories Ltd. | Instituted | Final written decision | All inst. claims upheld |
| IPR2018-00186 | Rituxan™ | 9,296,821 | 1-Dec-17 | Pfizer, Inc. | Biogen, Inc. | Instituted | Settled post-institution | N/A |
| IPR2018-00187 | | 9,492,559 | 20-Nov-17 | Sanofi S.A.; SK Chemicals Co., Ltd.; Sanofi Pasteur, Inc. | Pfizer, Inc. | Instituted | Final written decision | All claims unpatentable |
| IPR2018-00188 | | 9,492,559 | 20-Nov-17 | Sanofi S.A.; SK Chemicals Co., Ltd.; Sanofi Pasteur, Inc. | Pfizer, Inc. | Denied | N/A | N/A |
| IPR2018-00192 | | 7,846,441 | 30-Nov-17 | Samsung Bioepis Co., Ltd. | Genentech, Inc. | Denied | N/A | N/A |
| IPR2018-00211 | | 9,393,256 | 6-Dec-17 | Laura and John Arnold Foundation; Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | Gilead Pharmasset LLC | Denied | N/A | N/A |
| IPR2018-00231 | Rituxan™ | 9,504,744 | 1-Dec-17 | Pfizer, Inc. | Biogen, Inc. | N/A | Procedurally Dismissed | N/A |
| IPR2018-00249 | | 6,372,422 | 4-Dec-17 | Trans Ova Genetics, LC; Intrexon Corporation | XY, LLC | Denied | N/A | N/A |
| IPR2018-00250 | | 8,652,769 | 1-Dec-17 | Trans Ova Genetics, LC; Intrexon Corporation | XY, LLC | Instituted | Final written decision | All inst. claims upheld |
| IPR2018-00272 | Vimovo® | 9,393,208 | 4-Dec-17 | Mylan N.V.; Mylan, Inc.; Mylan Pharmaceuticals, Inc.; Mylan Technologies, Inc. | Horizon Pharma, Inc.; Pozen Inc. | Instituted | Pending | N/A |
| IPR2018-00285 | Rituxan™ | 8,329,172 | 14-Dec-17 | Pfizer, Inc. | Biogen, Inc. | Instituted | Settled post-institution | N/A |
| IPR2018-00290 | Mydayis® | 8,846,100 | 11-Dec-17 | KVK-Tech, Inc.; Abhai, LLC | Shire PLC | Instituted | Final written decision | All inst. claims upheld |
| IPR2018-00291 | | 9,718,852 | 8-Dec-17 | llumina, Inc. | The Trustees of Columbia University in the City of New York | Instituted | Final written decision | All claims unpatentable |
| IPR2018-00293 | Mydayis® | 9,173,857 | 11-Dec-17 | KVK-Tech, Inc.; Abhai, LLC | Shire PLC | Instituted | Final written decision | All inst. claims upheld |
| IPR2018-00295 | | 9,320,765 | 15-Dec-17 | Bioriginal Food & Science Corp.; Rimfrost New Zealand Ltd.; Emerald Fisheries AS; Rimfrost USA, LLC; et al. | Aker BioMarine Antarctic AS | Instituted | Final written decision | All claims unpatentable |
| IPR2018-00318 | | 9,719,139 | 15-Dec-17 | llumina, Inc. | The Trustees of Columbia University in the City of New York | Instituted | Final written decision | All claims unpatentable |
| IPR2018-00322 | | 9,708,358 | 18-Dec-17 | llumina, Inc. | The Trustees of Columbia University in the City of New York | Instituted | Final written decision | All claims unpatentable |

| | | | | | | | | |
|---------------|---|-----------|-----------|---|---|-----------------------------|--------------------------|-------------------------|
| IPR2018-00323 | | 9,675,621 | 19-Dec-17 | Provepharm Life Solutions; Provepharm SAS; Provepharm Inc. | Wista Laboratories Ltd. | Instituted | Final written decision | All inst. claims upheld |
| IPR2018-00330 | Herceptin® | 6,339,142 | 18-Dec-17 | Pfizer, Inc. | Genentech, Inc. | Denied | N/A | N/A |
| IPR2018-00331 | Herceptin® | 9,249,218 | 18-Dec-17 | Pfizer, Inc. | Genentech, Inc. | Denied | N/A | N/A |
| IPR2018-00373 | Avastin® | 9,795,672 | 5-Jan-18 | Pfizer, Inc. | Genentech, Inc. | Denied | N/A | N/A |
| IPR2018-00385 | | 9,725,480 | 22-Dec-17 | llumina, Inc. | The Trustees of Columbia University in the City of New York | Instituted | Final written decision | All claims unpatentable |
| IPR2018-00390 | Sovaldi®; Harvoni®; Eplclusa®; Vosevi™ | 8,889,159 | 26-Dec-17 | Laura and John Arnold Foundation; Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | Gilead Pharmasset LLC | Denied | N/A | N/A |
| IPR2018-00393 | | 9,636,402 | 22-Dec-17 | Organon USA, Inc.; Merck Sharp & Dohme; Merck Sharp & Dohme Corp. | Microspherix LLC | Instituted | Final written decision | All claims unpatentable |
| IPR2018-00402 | | 9,636,401 | 29-Dec-17 | Organon USA, Inc.; Merck Sharp & Dohme; Merck Sharp & Dohme Corp. | Microspherix LLC | Instituted | Final written decision | All inst. claims upheld |
| IPR2018-00405 | | 9,562,263 | 29-Dec-17 | EnviroLogix Inc. | Ionian Technologies, Inc. | Denied | N/A | N/A |
| IPR2018-00406 | | 9,562,264 | 29-Dec-17 | EnviroLogix Inc. | Ionian Technologies, Inc. | Denied | N/A | N/A |
| IPR2018-00421 | | 9,693,978 | 14-Jan-18 | Catalent Pharma Solutions, Inc. | Patheon Softgels Inc. | Denied | N/A | N/A |
| IPR2018-00422 | | 9,693,979 | 14-Jan-18 | Catalent Pharma Solutions, Inc. | Patheon Softgels Inc. | Denied | N/A | N/A |
| IPR2018-00423 | Viibryd® | 8,673,921 | 5-Jan-18 | APS GP LLC; Argentum Pharmaceuticals LLC; APS GP Investors LLC; et al. | Merck Patentgesellschaft | Denied | N/A | N/A |
| IPR2018-00431 | | 9,352,037 | 8-Jan-18 | Forty Seven, Inc. | Stichting Sanquin Bloedvoorziening | Settled pre- institution | N/A | N/A |
| IPR2018-00459 | Ravicti® | 9,561,197 | 12-Jan-18 | Lupin Pharmaceuticals, Inc.; Lupin Ltd. | Horizon Therapeutics, LLC | Settled pre- institution | N/A | N/A |
| IPR2018-00507 | Afinitor® | 8,410,131 | 17-Jan-18 | Hikma Pharmaceuticals PLC; West-Ward Pharmaceuticals International Ltd. | Novartis Pharmaceuticals Corp. | Instituted | Settled post-institution | N/A |
| IPR2018-00530 | Fortamet®; Actoplus Met® XR | 6,790,459 | 24-Jan-18 | Aurobindo Pharma USA, Inc. | Andrx Corp.; Andrx Labs, LLC; Andrx Laboratories, Inc.; Andrx Laboratories (NJ), Inc.; Andrx EU Ltd.; et al. | Denied | N/A | N/A |
| IPR2018-00566 | | 9,074,262 | 6-Feb-18 | Grifols Diagnostics Solutions, Inc.; Grifols Worldwide Operations Ltd.; et al. | Biomeriux, Inc. | Denied | N/A | N/A |

| | | | | | | | | |
|---------------|------------|-----------|-----------|--|---|------------|--------------------------|-------------------------|
| IPR2018-00567 | | 9,074,262 | 6-Feb-18 | Grifols Diagnostics Solutions, Inc.; Grifols Worldwide Operations Ltd.; et al. | Biomeriux, Inc. | Denied | N/A | N/A |
| IPR2018-00568 | | 8,697,352 | 6-Feb-18 | Grifols Diagnostics Solutions, Inc.; Grifols Worldwide Operations Ltd.; et al. | Biomeriux, Inc. | Denied | N/A | N/A |
| IPR2018-00569 | | 8,697,352 | 6-Feb-18 | Grifols Diagnostics Solutions, Inc.; Grifols Worldwide Operations Ltd.; et al. | Biomeriux, Inc. | Denied | N/A | N/A |
| IPR2018-00602 | | 8,821,835 | 9-Feb-18 | Organon USA, Inc.; Merck Sharp & Dohme; Merck Sharp & Dohme Corp. | Microspherix LLC | Instituted | Final written decision | All inst. claims upheld |
| IPR2018-00608 | Dapsone | 9,161,926 | 12-Feb-18 | Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals of New York LLC | Allergan, Inc. | Instituted | Pending | N/A |
| IPR2018-00625 | OxyContin® | 9,492,392 | 27-Feb-18 | Kashiv Pharma, LLC | Purdue Pharma L.P.; The P.F. Laboratories, Inc. | N/A | Settled pre-institution | N/A |
| IPR2018-00680 | | 9,404,127 | 21-Feb-18 | Moderna Therapeutics, Inc. | Protiva Biotherapeutics, Inc. | Instituted | Pending | N/A |
| IPR2018-00685 | Revlimid® | 8,741,929 | 23-Feb-18 | Apotex Inc. | Celgene Corporation | Denied | N/A | N/A |
| IPR2018-00717 | OxyContin® | 9,492,392 | 28-Feb-18 | Kashiv Pharma, LLC | Purdue Pharma L.P.; The P.F. Laboratories, Inc. | N/A | Settled pre-institution | N/A |
| IPR2018-00739 | | 9,364,435 | 5-Mar-18 | Moderna Therapeutics, Inc. | Protiva Biotherapeutics, Inc. | Instituted | Pending | N/A |
| IPR2018-00778 | | 6,423,327 | 15-Mar-18 | L'Oréal USA, Inc.; L'Oréal S.A. | University of Massachusetts Medical School; Carmel Labs, LLC. | Denied | N/A | N/A |
| IPR2018-00779 | | 6,645,513 | 20-Mar-18 | L'Oréal USA, Inc.; L'Oréal S.A. | University of Massachusetts Medical School; Carmel Labs, LLC. | Denied | N/A | N/A |
| IPR2018-00789 | | 9,546,400 | 15-Mar-18 | Oxford Nanopore Technologies, Inc.; Metrichor, Ltd., Oxford Nanopore Techs. Ltd. | Pacific Biosciences of California, Inc. | Denied | N/A | N/A |
| IPR2018-00795 | | 9,370,512 | 16-Mar-18 | Indivior, Inc. | Rhodes Pharmaceuticals L.P. | Denied | N/A | N/A |
| IPR2018-00797 | | 9,868,985 | 16-Mar-18 | Illumina, Inc. | The Trustees of Columbia University in the City of New York | Instituted | Pending | N/A |
| IPR2018-00892 | Eliquis® | 9,326,945 | 5-Apr-18 | Mylan, Inc.; Mylan N.V.; Mylan Pharmaceuticals, Inc. | Pfizer, Inc.; Bristol-Myers Squibb Company | Instituted | Settled post-institution | N/A |

| | | | | | | | | |
|---------------|-----------|-----------|-----------|---|---|-----------------------------|--------------------------|-------------------------|
| IPR2018-00894 | Vimovo® | 9,220,698 | 6-Apr-18 | Dr. Reddy's Laboratories, Ltd.; Dr. Reddy's Laboratories, Inc. | Horizon Pharma, Inc.; Pozen Inc. | Instituted | Procedurally Dismissed | N/A |
| IPR2018-00919 | | 8,008,001 | 13-Apr-18 | Boehringer Ingelheim Vetmedica, Inc.; Merial, Inc.; | Boehringer Ingelheim GmbH | Intervet International B.V. | Denied | N/A |
| IPR2018-00943 | Vivitrol® | 7,919,499 | 20-Apr-18 | Amneal Pharmaceuticals LLC | Alkermes Pharma Ireland Limited | Instituted | Settled post-institution | N/A |
| IPR2018-00948 | | 8,728,806 | 18-Apr-18 | Baylor College of Medicine and Diakonos Research, Ltd. | The Board of Regents of the University of Texas System and Gensetix, Inc. | N/A | Pending | N/A |
| IPR2018-00949 | | 9,333,248 | 18-Apr-18 | Baylor College of Medicine and Diakonos Research, Ltd. | The Board of Regents of the University of Texas System and Gensetix, Inc. | N/A | Pending | N/A |
| IPR2018-00974 | | 9,655,945 | 27-Apr-18 | Research Products Corp. | Honeywell International, Inc. | Instituted | Pending | N/A |
| IPR2018-01019 | Rituxan™ | 7,976,838 | 4-May-18 | Celltrion, Inc. | Genentech, Inc. | Instituted | Final written decision | All inst. claims upheld |
| IPR2018-01020 | Pazeo™ | 8,791,154 | 5-Jun-18 | InvaGen Pharmaceuticals, Inc.; Cipla Ltd.; Cipla (EU) Limited; Cipla USA, Inc. | Alcon Research Ltd. | N/A | Settled pre-institution | N/A |
| IPR2018-01021 | Pazeo™ | 9,533,053 | 5-Jun-18 | InvaGen Pharmaceuticals, Inc.; Cipla Ltd.; Cipla (EU) Limited; Cipla USA, Inc. | Alcon Research Ltd. | N/A | Settled pre-institution | N/A |
| IPR2018-01096 | | 7,816,392 | 15-May-18 | Willowood USA, LLC; Greenfields Marketing Ltd. | BASF SE | Denied | N/A | N/A |
| IPR2018-01119 | Xarelto® | 9,539,218 | 18-May-18 | Mylan, Inc.; Mylan Pharmaceuticals, Inc.; Mylan N.V. | Noven Pharmaceuticals, Inc. | N/A | Settled pre-institution | N/A |
| IPR2018-01143 | | 9,333,248 | 24-May-18 | Mylan N.V.; Mylan Pharmaceuticals, Inc.; Mylan Technologies, Inc. | Bayer Intellectual Property GMBH | Denied | N/A | N/A |
| IPR2018-01178 | | 9,375,453 | 26-Jun-18 | Bioriginal Food & Science Corp.; Rimfrost New Zealand Ltd.; Emerald Fisheries AS; | Rimfrost USA, LLC; et al. | Aker BioMarine Antarctic AS | Instituted | Pending |
| IPR2018-01179 | | 9,375,453 | 26-Jun-18 | Bioriginal Food & Science Corp.; Rimfrost New Zealand Ltd.; Emerald Fisheries AS; | Rimfrost USA, LLC; et al. | Aker BioMarine Antarctic AS | Instituted | Pending |
| IPR2018-01183 | Cialis® | 6,943,166 | 7-Jun-18 | Aquestive Therapeutics Inc. | ICOS Corporation | Denied | N/A | N/A |
| IPR2018-01194 | | 9,193,873 | 4-Jun-18 | Reactive Surfaces Ltd., LLP | Toyota Motor Corp. | Denied | N/A | N/A |
| IPR2018-01219 | | 8,314,225 | 14-Jun-18 | Pfizer, Inc. | Hoffman-La Roche, Inc. | Instituted | Pending | N/A |
| IPR2018-01224 | | 9,365,822 | 8-Jun-18 | ABS Global, Inc.; Genus plc | XY, LLC | Instituted | Pending | N/A |

| | | | | | | | | |
|---------------|----------|-----------|-----------|---|---|------------|-------------------------|-----|
| IPR2018-01229 | | 8,753,645 | 11-Jun-18 | Merck & Co., Inc.; Merck Sharpe & Dohme Corp. | GlaxoSmithKline Biologicals, S.A. | Instituted | Pending | N/A |
| IPR2018-01234 | | 9,265,839 | 11-Jun-18 | Merck & Co., Inc.; Merck Sharpe & Dohme Corp. | GlaxoSmithKline Biologicals, S.A. | Instituted | Pending | N/A |
| IPR2018-01236 | | 8,753,645 | 11-Jun-18 | Merck & Co., Inc.; Merck Sharpe & Dohme Corp. | GlaxoSmithKline Biologicals, S.A. | Instituted | Pending | N/A |
| IPR2018-01237 | | 9,265,839 | 11-Jun-18 | Merck & Co., Inc.; Merck Sharpe & Dohme Corp. | GlaxoSmithKline Biologicals, S.A. | Instituted | Pending | N/A |
| IPR2018-01287 | | 9,469,640 | 18-Jun-18 | Novartis Pharmaceuticals Corporation | Plexicon, Inc. | Denied | N/A | N/A |
| IPR2018-01313 | | 9,623,091 | 2-Jul-18 | CSL Limited; CSL Behring Beteiligungs-und Verwaltungs GmbH & Co. (KG); et al. | Bioerativ Therapeutics Inc. | Denied | N/A | N/A |
| IPR2018-01317 | | 9,493,831 | 29-Jun-18 | Natera, Inc. | Illumina, Inc. | Denied | N/A | N/A |
| IPR2018-01341 | Vimovo® | 9,393,208 | 2-Jul-18 | Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories, Ltd. | Pozen Inc.; Horizon Pharma Inc. | N/A | Pending | N/A |
| IPR2018-01345 | | 9,623,091 | 6-Jul-18 | CSL Limited; CSL Behring Beteiligungs-und Verwaltungs GmbH & Co. (KG); et al. | Bioerativ Therapeutics Inc. | Denied | N/A | N/A |
| IPR2018-01347 | | 9,085,799 | 3-Jul-18 | Thermo Fisher Scientific, Inc.; Affymetrix, Inc.; Life Technologies Corporation | University of California | Denied | N/A | N/A |
| IPR2018-01358 | Kerydin™ | 9,549,938 | 6-Jul-18 | Mylan Pharmaceuticals, Inc.; Mylan Inc.; Mylan N.V. | Anacor Pharmaceuticals, Inc. | Instituted | Pending | N/A |
| IPR2018-01359 | Kerydin™ | 9,566,289 | 6-Jul-18 | Mylan Pharmaceuticals, Inc.; Mylan Inc.; Mylan N.V. | Anacor Pharmaceuticals, Inc. | Instituted | Pending | N/A |
| IPR2018-01360 | Kerydin™ | 9,566,290 | 10-Jul-18 | Mylan Pharmaceuticals, Inc.; Mylan Inc.; Mylan N.V. | Anacor Pharmaceuticals, Inc. | Instituted | Pending | N/A |
| IPR2018-01361 | Kerydin™ | 9,572,823 | 10-Jul-18 | Mylan Pharmaceuticals, Inc.; Mylan Inc.; Mylan N.V. | Anacor Pharmaceuticals, Inc. | Instituted | Pending | N/A |
| IPR2018-01363 | | 8,101,579 | 6-Jul-18 | Synergy Pharmaceuticals Inc. | Ironwood Pharmaceuticals, Inc. | N/A | Settled pre-institution | N/A |
| IPR2018-01367 | | 8,835,113 | 10-Jul-18 | Affymetrix, Inc.; Thermo Fisher Scientific Inc.; Life Technologies Corporation | The Regents of the University of California | Denied | N/A | N/A |
| IPR2018-01368 | | 8,835,113 | 10-Jul-18 | Affymetrix, Inc.; Thermo Fisher Scientific Inc.; Life Technologies Corporation | The Regents of the University of California | Denied | N/A | N/A |

| | | | | | | | | |
|---------------|----------------------|-----------|-----------|---|---|-------------------------|---------|-----|
| IPR2018-01369 | | 8,110,673 | 10-Jul-18 | Affymetrix, Inc.; Thermo Fisher Scientific Inc.; Life Technologies Corporation | The Regents of the University of California | Denied | N/A | N/A |
| IPR2018-01370 | | 8,110,673 | 10-Jul-18 | Affymetrix, Inc.; Thermo Fisher Scientific Inc.; Life Technologies Corporation | The Regents of the University of California | Denied | N/A | N/A |
| IPR2018-01375 | | 8,859,832 | 3-Aug-18 | REG Synthetic Fuels, LLC | Neste Oile, OYJ | Instituted | Pending | N/A |
| IPR2018-01403 | Tecfidera® | 8,399,514 | 13-Jul-18 | Mylan Laboratories Limited; Mylan N.V.; Mylan Pharmaceuticals, Inc.; Mylan, Inc. | Biogen MA Inc. | Instituted | Pending | N/A |
| IPR2018-01422 | Ajovy®/ Emgality® | 9,340,614 | 8-Aug-18 | Eli Lilly & Co | Teva Pharmaceuticals International GmbH | Instituted | Pending | N/A |
| IPR2018-01423 | Ajovy®/ Emgality® | 9,266,951 | 8-Aug-18 | Eli Lilly & Co | Teva Pharmaceuticals International GmbH | Instituted | Pending | N/A |
| IPR2018-01424 | Ajovy®/ Emgality® | 9,346,881 | 8-Aug-18 | Eli Lilly & Co | Teva Pharmaceuticals International GmbH | Instituted | Pending | N/A |
| IPR2018-01425 | Ajovy®/ Emgality® | 9,890,210 | 8-Aug-18 | Eli Lilly & Co | Teva Pharmaceuticals International GmbH | Instituted | Pending | N/A |
| IPR2018-01426 | Ajovy®/ Emgality® | 9,890,211 | 8-Aug-18 | Eli Lilly & Co | Teva Pharmaceuticals International GmbH | Instituted | Pending | N/A |
| IPR2018-01427 | Ajovy®/ Emgality® | 8,597,649 | 8-Aug-18 | Eli Lilly & Co | Teva Pharmaceuticals International GmbH | Instituted | Pending | N/A |
| IPR2018-01494 | Korlym™ | 8,921,348 | 2-Aug-18 | Neptune Generics, LLC | Corcept Therapeutics Inc. | Instituted | Pending | N/A |
| IPR2018-01504 | Revlimid® | 9,056,120 | 3-Aug-18 | Dr. Reddy's Laboratories, Inc. | Celgene Corporation | Denied | N/A | N/A |
| IPR2018-01507 | Revlimid® | 8,404,717 | 3-Aug-18 | Dr. Reddy's Laboratories, Inc. | Celgene Corporation | Denied | N/A | N/A |
| IPR2018-01509 | Revlimid® | 7,189,740 | 3-Aug-18 | Dr. Reddy's Laboratories, Inc. | Celgene Corporation | Denied | N/A | N/A |
| IPR2018-01516 | | 8,784,854 | 6-Aug-18 | Cosmax USA, Corp.: Cosmax Co. Ltd. | AMorePacific Corp. | Denied | N/A | N/A |
| IPR2018-01520 | | 8,932,717 | 6-Aug-18 | Reactive Surfaces Ltd., LLP | LG Chem Ltd. | Instituted | Pending | N/A |
| IPR2018-01550 | Ravicti® | 9,561,197 | 21-Aug-18 | Endo Luxembourg Holding Co. S.a.r.l.; Endo Int'l. PLC; Par Pharmaceutical, Inc.; Endo DAC; et al. | Horizon Therapeutics, LLC | Settled pre-institution | N/A | N/A |
| IPR2018-01566 | | 8,367,337 | 21-Aug-18 | Becton, Dickinson and Co. | Biomeriux, Inc. | Instituted | Pending | N/A |
| IPR2018-01640 | | 9,353,050 | 31-Aug-18 | Luitpold Pharmaceuticals, Inc. | Apicore US LLC | Denied | N/A | N/A |
| IPR2018-01710 | | 8,586,045 | 28-Sep-18 | Eli Lilly and Co. | Teva Pharmaceuticals International GmbH | Instituted | Pending | N/A |

| | | | | | | | |
|---------------|------------------------|-----------|---|---|-------------------------|-------------------------|-----|
| IPR2018-01711 | 9,884,907 | 1-Oct-18 | Eli Lilly and Co. | Teva Pharmaceuticals International GmbH | Instituted | Pending | N/A |
| IPR2018-01712 | 9,884,908 | 1-Oct-18 | Eli Lilly and Co. | Teva Pharmaceuticals International GmbH | Instituted | Pending | N/A |
| IPR2018-01714 | Revlimid® 7,968,569 | 1-Sep-18 | Alvogen Pine Brook LLC; Lotus Pharmaceutical Co., Ltd. | Celgene Corporation | Denied | N/A | N/A |
| IPR2018-01730 | 9,072,752 | 21-Sep-18 | Rimfrost AS | Aker BioMarine Antarctic AS | Instituted | Pending | N/A |
| IPR2018-01766 | 9,428,450 | 28-Sep-18 | China Grand Enterprises, Inc.; Hubei Grand Life Science and Technology Co., Ltd. et al. | Vitaworks IP, LLC | Instituted | Pending | N/A |
| IPR2018-01767 | 9,428,451 | 28-Sep-18 | China Grand Enterprises, Inc.; Hubei Grand Life Science and Technology Co., Ltd. et al. | Vitaworks IP, LLC | Instituted | Pending | N/A |
| IPR2018-01768 | 9,573,890 | 28-Sep-18 | China Grand Enterprises, Inc.; Hubei Grand Life Science and Technology Co., Ltd. et al. | Vitaworks IP, LLC | Instituted | Pending | N/A |
| IPR2018-01781 | 9,790,543 | 24-Sep-18 | Agilent Technologies, Inc. | Roche Sequencing Solutions, Inc. | Instituted | Pending | N/A |
| IPR2018-01785 | 9,738,929 | 24-Sep-18 | Oxford Nanopore Technologies, Inc.; Metrichor, Ltd., Oxford Nanopore Techs. Ltd. | Pacific Biosciences of California, Inc. | Settled pre-institution | N/A | N/A |
| IPR2018-01788 | 9,011,872 | 24-Sep-18 | Merck & Co., Inc.; Intervet Inc. DBA Merch Animal Health; Intervet International B.V. | Boehringer Ingelheim Vetmedica, Inc. | Denied | N/A | N/A |
| IPR2018-01789 | 9,011,872 | 24-Sep-18 | Merck & Co., Inc.; Intervet Inc. DBA Merch Animal Health; Intervet International B.V. | Boehringer Ingelheim Vetmedica, Inc. | Denied | N/A | N/A |
| IPR2018-01792 | 9,738,929 | 25-Sep-18 | Oxford Nanopore Technologies, Inc.; Metrichor, Ltd., Oxford Nanopore Techs. Ltd. | Pacific Biosciences of California, Inc. | Denied | N/A | N/A |
| IPR2018-01795 | 9,678,056 | 25-Sep-18 | Oxford Nanopore Technologies, Inc.; Metrichor, Ltd., Oxford Nanopore Techs. Ltd. | Pacific Biosciences of California, Inc. | N/A | Settled pre-institution | N/A |